Beam sues over alleged IP theft as Moderna appoints new COO and Pierre Fabre/Atara refile drug for ultra-rare blood cancer
Beam Therapeutics has filed a lawsuit claiming a former scientist took proprietary information and used it to start a Chinese firm, alleging theft of its intellectual property.
PhRMA announced a new leader for its lobbying efforts, though details of the appointment were not disclosed in the brief report.
Moderna named Juan Andres as chief operating officer, marking his second tenure at the company after previously overseeing manufacturing and quality control as it expands into oncology.
Pierre Fabre Pharmaceuticals and Atara Biotherapeutics have refiled their candidate Ebvallo with the FDA, seeking approval to treat an ultra‑rare, fatal blood cancer that can arise after stem‑cell or organ transplantation, following a prior rejection earlier in the year.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Three biotech updates, including accusations of theft and and a new lobbying leader”
read at STAT ↗
comments(0)
5-min edit window · permanent after that